Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01298518 · ClinicalTrials.gov registry record · Phase 1
A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT01298518 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 48 participants.
The verdict
NCT01298518, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.
Interventions
- DRUG Placebo
- DRUG PF-04620110
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2011-02 |
| Est. Completion | 2011-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01298518
The ClinicalTrials.gov registry entry for NCT01298518 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01298518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01298518 about?
NCT01298518 is a clinical study titled "A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients". PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The primary purpose of this trial is to evaluate the safety and tolerability, and pharmacodynamics, of multiple oral doses of PF-04620110 in T2DM patients.
What is the current status of trial NCT01298518?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2011-02. Estimated completion is 2011-05.
What interventions are being tested in trial NCT01298518?
The interventions under investigation include: Placebo (DRUG), PF-04620110 (DRUG).
Who is sponsoring clinical trial NCT01298518?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.